首页 | 本学科首页   官方微博 | 高级检索  
     


NRG/RTOG 1122: A phase 2, double-blinded,placebo-controlled study of bevacizumab with and without trebananib in patients with recurrent glioblastoma or gliosarcoma
Authors:Eudocia Q. Lee MD  Peixin Zhang PhD  Patrick Y. Wen MD  Elizabeth R. Gerstner MD  David A. Reardon MD  Kenneth D. Aldape MD  John F. deGroot MD  Edward Pan MD  Jeffrey J. Raizer MD  Lyndon J. Kim MD  Steven J. Chmura MD  H. Ian Robins MD  Jennifer M. Connelly MD  James D. Battiste MD  John L. Villano MD  Naveed Wagle MD  Ryan T. Merrell MD  Merideth M. Wendland MD  Minesh P. Mehta MD
Affiliation:1. Dana-Farber/Brigham and Women's Cancer Center, Boston, Massachusetts;2. NRG Oncology Statistics and Data Management Center, American College of Radiology, Philadelphia, Pennsylvania;3. Massachusetts General Hospital, Boston, Massachusetts;4. Toronto General Hospital, Toronto, Ontario, Canada;5. The University of Texas MD Anderson Cancer Center, Houston, Texas;6. University of Texas Southwestern Medical Center, Dallas, Texas;7. Northwestern University, Evanston, Illinois;8. Thomas Jefferson University Hospital, Philadelphia, Pennsylvania;9. University of Chicago Comprehensive Cancer Center, Chicago, Illinois;10. University of Wisconsin Hospital and Clinics, Madison, Wisconsin;11. Froedtert and the Medical College of Wisconsin, Milwaukee, Wisconsin;12. University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma;13. University of Kentucky, Lexington, Kentucky;14. University of Southern California, Los Angeles, California;15. North Shore University Health System, Evanston, Illinois;16. The US Oncology Network-Willamette Valley Cancer Institute, Eugene, Oregon;17. Baptist Hospital of Miami, Miami, Florida
Abstract:
Keywords:angiogenesis  angiopoietin  bevacizumab  glioblastoma  trebananib
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号